← Research library

Ezrin-derived peptides and pharmaceutical compositions — US9682140B2

Patent disclosure · 2017

What the patent describes
Ezrin-related patent chemistry and experimental examples
Reported evidence
The granted claim class defines modified ezrin-derived peptides, including GEKKRRETVEREGG. A dependent composition also includes the parent Gepon sequence TEKKRRETVEREKE. Modified peptides and mixtures must not inherit Gepon clinical outcomes.

Phospho-ERK1 · 0.40 ± 0.02 after HP-V2 versus 0.10 ± 0.002 negative control · Normalized laboratory signal; positive TGF-β1 control 0.50 ± 0.02 · 1 hour · p<0.01

Reported patent results

Reported findings

The modified peptide increased MAPK/ERK phosphorylation in cell cultures.

Fibroblast signaling experiments with modified ezrin-derived HP-V2; a different sequence from parent Gepon.

Population or model Ezrin-related patent chemistry and experimental examples

Results · Final fibroblast MAPK/ERK experiment; modified-peptide identity explicitly retained.
MeasureResultComparison, timing and statistics
Phospho-ERK10.40 ± 0.02 after HP-V2 versus 0.10 ± 0.002 negative controlNormalized laboratory signal; positive TGF-β1 control 0.50 ± 0.02 · 1 hour · p<0.01
Phospho-ERK21.30 ± 0.05 versus 0.40 ± 0.01 negative controlPositive TGF-β1 control 1.90 ± 0.10 · 1 hour · p<0.01

A fibroblast pathway response does not prove tissue repair or clinical efficacy. Values belong to HP-V2, not automatically Gepon, related fragments or every mixture.

Source for these results ↗ · Reviewed 2026-11-06

Patent claims and provenance

Molecule. Ezrin-derived peptide and composition claims; the claimed modified sequences are not automatically identical to the parent Gepon peptide or every marketed formulation.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
US9682140B2 ↗ · 2017-06-20
Earliest priority / filing
2015-06-01 / 2016-06-01
Original applicant / assignee
Nearmedic International Ltd
Indexed status
Active · checked 2026-11-06
Patent family
56117690 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Ezrin-derived peptides and pharmaceutical compositions thereof

Inventors: Rupert Holms; Ravshan Ataullakhanov; Rustam Ataullakhanov; Khachik Sayadyan.

US9682140B2 · EP3191504B1 · JP6721419B2 · KR101842978B1 · CN106188267B · AU2016203656B2 · CA2931875C · CY1120501T1 · DK3191504T3 · ES2660894T3 · GB2546439B · HRP20180560T1 · HUE038737T2 · LT3191504T · MA39421A · MD3191504T2 · ME03033B · MX377333B · PL3191504T3 · PT3191504T · RS57067B1 · SG10201604401UA · SI3191504T1 · SMT201800190T1 · WO2016193285A1 · ZA201603723B

Original patent PDF ↗

Patent collection and status interpretation →

Study limitations and source details

Study limitations

  • Modified sequences and mixtures must not inherit Gepon outcomes.
  • Clinical evidence appraisal remains pending.

Source details

Selected original-source text checked; full methodological review pending.

Selected text reviewed

Sources checked

Citation

Patent / reported experimentsFull text available

Author unconfirmed. Ezrin-derived peptides and pharmaceutical compositions — US9682140B2 Primary source linked above

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards